Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 15 studies | 34% ± 20% | |
lung | 9 studies | 23% ± 7% | |
eye | 8 studies | 28% ± 9% | |
peripheral blood | 4 studies | 22% ± 2% | |
liver | 4 studies | 33% ± 17% | |
adipose | 4 studies | 22% ± 3% | |
pancreas | 3 studies | 33% ± 14% | |
heart | 3 studies | 18% ± 1% | |
bone marrow | 3 studies | 19% ± 6% | |
intestine | 3 studies | 22% ± 5% | |
kidney | 3 studies | 19% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 17880.42 | 2642 / 2642 | 100% | 242.62 | 705 / 705 |
prostate | 100% | 10782.23 | 245 / 245 | 100% | 100.72 | 502 / 502 |
stomach | 100% | 10427.25 | 359 / 359 | 100% | 137.44 | 286 / 286 |
lung | 100% | 14043.72 | 578 / 578 | 100% | 119.13 | 1152 / 1155 |
thymus | 100% | 13914.61 | 653 / 653 | 100% | 135.04 | 603 / 605 |
intestine | 100% | 11370.47 | 966 / 966 | 99% | 137.32 | 524 / 527 |
breast | 100% | 12800.16 | 459 / 459 | 99% | 207.34 | 1110 / 1118 |
kidney | 100% | 13200.65 | 89 / 89 | 99% | 127.86 | 894 / 901 |
skin | 100% | 10539.81 | 1808 / 1809 | 99% | 134.30 | 468 / 472 |
esophagus | 100% | 11580.67 | 1439 / 1445 | 99% | 135.77 | 181 / 183 |
bladder | 100% | 12224.19 | 21 / 21 | 98% | 99.76 | 492 / 504 |
ovary | 100% | 13267.97 | 180 / 180 | 97% | 63.47 | 417 / 430 |
pancreas | 97% | 4906.41 | 317 / 328 | 99% | 117.38 | 176 / 178 |
adrenal gland | 100% | 10761.69 | 258 / 258 | 94% | 88.65 | 216 / 230 |
uterus | 100% | 11420.27 | 170 / 170 | 88% | 80.34 | 405 / 459 |
liver | 89% | 3152.89 | 201 / 226 | 77% | 41.61 | 311 / 406 |
adipose | 100% | 11944.20 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 10268.00 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 69.02 | 29 / 29 |
spleen | 100% | 9913.69 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 33.42 | 1 / 1 |
muscle | 100% | 7739.71 | 801 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 8059.63 | 920 / 929 | 0% | 0 | 0 / 0 |
heart | 99% | 8912.09 | 849 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 68.52 | 44 / 45 |
eye | 0% | 0 | 0 / 0 | 98% | 101.59 | 78 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0035904 | Biological process | aorta development |
GO_0098884 | Biological process | postsynaptic neurotransmitter receptor internalization |
GO_0048488 | Biological process | synaptic vesicle endocytosis |
GO_0001822 | Biological process | kidney development |
GO_0006886 | Biological process | intracellular protein transport |
GO_0060976 | Biological process | coronary vasculature development |
GO_0003281 | Biological process | ventricular septum development |
GO_0016192 | Biological process | vesicle-mediated transport |
GO_0072583 | Biological process | clathrin-dependent endocytosis |
GO_0098978 | Cellular component | glutamatergic synapse |
GO_0098793 | Cellular component | presynapse |
GO_0005886 | Cellular component | plasma membrane |
GO_0030122 | Cellular component | AP-2 adaptor complex |
GO_0016020 | Cellular component | membrane |
GO_0030666 | Cellular component | endocytic vesicle membrane |
GO_0009898 | Cellular component | cytoplasmic side of plasma membrane |
GO_0030669 | Cellular component | clathrin-coated endocytic vesicle membrane |
GO_0098794 | Cellular component | postsynapse |
GO_0030131 | Cellular component | clathrin adaptor complex |
GO_0005829 | Cellular component | cytosol |
GO_0045334 | Cellular component | clathrin-coated endocytic vesicle |
GO_0036020 | Cellular component | endolysosome membrane |
GO_0005048 | Molecular function | signal sequence binding |
GO_0035615 | Molecular function | clathrin adaptor activity |
GO_0030276 | Molecular function | clathrin binding |
GO_0005515 | Molecular function | protein binding |
Gene name | AP2B1 |
Protein name | Adaptor related protein complex 2 subunit beta 1 AP complex subunit beta AP-2 complex subunit beta (AP105B) (Adaptor protein complex AP-2 subunit beta) (Adaptor-related protein complex 2 subunit beta) (Beta-2-adaptin) (Beta-adaptin) (Clathrin assembly protein complex 2 beta large chain) (Plasma membrane adaptor HA2/AP2 adaptin beta subunit) |
Synonyms | CLAPB1 ADTB2 hCG_1992160 |
Description | FUNCTION: Component of the adaptor protein complex 2 (AP-2). Adaptor protein complexes function in protein transport via transport vesicles in different membrane traffic pathways. Adaptor protein complexes are vesicle coat components and appear to be involved in cargo selection and vesicle formation. AP-2 is involved in clathrin-dependent endocytosis in which cargo proteins are incorporated into vesicles surrounded by clathrin (clathrin-coated vesicles, CCVs) which are destined for fusion with the early endosome. The clathrin lattice serves as a mechanical scaffold but is itself unable to bind directly to membrane components. Clathrin-associated adaptor protein (AP) complexes which can bind directly to both the clathrin lattice and to the lipid and protein components of membranes are considered to be the major clathrin adaptors contributing the CCV formation. AP-2 also serves as a cargo receptor to selectively sort the membrane proteins involved in receptor-mediated endocytosis. AP-2 seems to play a role in the recycling of synaptic vesicle membranes from the presynaptic surface. AP-2 recognizes Y-X-X-[FILMV] (Y-X-X-Phi) and [ED]-X-X-X-L-[LI] endocytosis signal motifs within the cytosolic tails of transmembrane cargo molecules. AP-2 may also play a role in maintaining normal post-endocytic trafficking through the ARF6-regulated, non-clathrin pathway. During long-term potentiation in hippocampal neurons, AP-2 is responsible for the endocytosis of ADAM10 . The AP-2 beta subunit acts via its C-terminal appendage domain as a scaffolding platform for endocytic accessory proteins; at least some clathrin-associated sorting proteins (CLASPs) are recognized by their [DE]-X(1,2)-F-X-X-[FL]-X-X-X-R motif. The AP-2 beta subunit binds to clathrin heavy chain, promoting clathrin lattice assembly; clathrin displaces at least some CLASPs from AP2B1 which probably then can be positioned for further coat assembly. . |
Accessions | ENST00000612035.4 ENST00000620039.4 K7EKZ5 P63010 A0A140VJE8 K7EN71 ENST00000614600.4 ENST00000590432.5 A0A087WU93 A0A087WXS3 A0A087WYD1 ENST00000610402.5 [P63010-2] ENST00000621914.4 [P63010-1] ENST00000612116.5 ENST00000587805.1 A0A087WZQ6 K7ERB2 K7EJX1 ENST00000593014.3 K7EMN7 ENST00000618940.4 [P63010-2] K7EJ01 A0A087X253 ENST00000616681.4 ENST00000628168.1 ENST00000588116.1 ENST00000592167.5 ENST00000591610.5 ENST00000589774.5 ENST00000590538.5 ENST00000616784.4 ENST00000621668.4 |